Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bristol-Myers Squibb CoXSWX:BMY 73 3-Year EPS without NRI Growth Rate is -7.20% as of Jun. 2026. GuruFocus rates XSWX:BMY with a GF Score™ of 73/100 and a GF Value™ of CHF45.70 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 785 Drug Manufacturers companies, Bristol-Myers Squibb Co ranks worse than 74.01% on this metric.
During the past 12 months, Bristol-Myers Squibb Co's average EPS without NRI Growth Rate was -1.80% per year.
During the past 3 years, the average EPS without NRI Growth Rate was -7.20% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -15.50% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 6.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Bristol-Myers Squibb Co was 36.10% per year. The lowest was -46.50% per year. And the median was 9.75% per year.
Bristol-Myers Squibb Co (XSWX:BMY) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Bristol-Myers Squibb Co 3-Year EPS without NRI Growth Rate Related Terms
XSWX:BMY vs PFE, GILD, AMGN: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's 3-Year EPS without NRI Growth Rate falls into.
Bristol-Myers Squibb Co 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of -7.20% mean?
Bristol-Myers Squibb Co (XSWX:BMY) has a 3-Year EPS without NRI Growth Rate of -7.20% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Bristol-Myers Squibb Co and its competitors. According to the industry distribution chart, Bristol-Myers Squibb Co ranks #581 out of 785 companies in the Drug Manufacturers industry, placing it in the top 74%.
Is Bristol-Myers Squibb Co's 3-Year EPS without NRI Growth Rate too high?
Bristol-Myers Squibb Co's current 3-Year EPS without NRI Growth Rate is -7.20%. Based on the distribution chart, Bristol-Myers Squibb Co ranks #581 out of 785 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bristol-Myers Squibb Co has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's 3-Year EPS without NRI Growth Rate compare to PFE and GILD?
According to the Drug Manufacturers industry distribution chart, Bristol-Myers Squibb Co ranks #581 out of 785 companies for 3-Year EPS without NRI Growth Rate. This places Bristol-Myers Squibb Co in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.90, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Bristol-Myers Squibb Co and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bristol-Myers Squibb Co's current 3-Year EPS without NRI Growth Rate is -7.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (XSWX:BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF45.70, compared to a current price of CHF54.34 — trading 18.9% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is -7.20%. Bristol-Myers Squibb Co's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Bristol-Myers Squibb Co (XSWX:BMY), the current 3-Year EPS without NRI Growth Rate is -7.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (XSWX:BMY) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of CHF54.34 is trading 18.9% above its estimated GF Value™ of CHF45.70.
GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.
Key valuation signals for XSWX:BMY:
3-Year EPS without NRI Growth Rate: -7.20%
GF Value™: CHF45.70 vs. price of CHF54.34 (18.9% above fair value)
No single metric tells the full story. See the XSWX:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
73GF Score
Get the complete analysis for XSWX:BMY
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BMY has been successfully added to your 
